BioCentury
ARTICLE | Company News

ProQR spins out Wings Therapeutics

March 29, 2019 6:38 PM UTC

ProQR spun out its dystrophic epidermolysis bullosa business into Wings Therapeutics.

Wings will continue to develop QR-313 to treat dystrophic epidermolysis bullosa patients with a mutation in exon 73. ProQR Therapeutics N.V. (NASDAQ:PRQR) will focus its development pipeline on ophthalmology programs...

BCIQ Company Profiles

ProQR Therapeutics N.V.